ロード中...
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
BACKGROUND: Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD must manage EIMs affecting multiple organs that variably correlate with intest...
保存先:
| 出版年: | Dig Dis Sci |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5854745/ https://ncbi.nlm.nih.gov/pubmed/29484571 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-018-4971-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|